Triana Biomedicines Raises $110M In Series A Funding


Triana Biomedicines raised $110M In Series A Funding, a Boston-based biotech company.

Lightspeed Venture Partners was the leader of the round, with participation by Surveyor Capital, Logos Capital and Pfizer Ventures.

The funds will be used to expand operations and support development efforts.

Triana Biomedicines is developing a molecular adhesive discovery platform that can regulate diseases targets that are hard to treat with any other method. The drug discovery engine uses high-resolution structural insights and AI, as well as computational tools and custom chemical libraries. The rational and targeted approach to molecular adhesive discovery is currently focused on the induction or enhancement of the degradation high-profile cancer targets.

The company is led by Dr. Patrick Trojer, President & CEO, Dr. Jesse Chen, CTO and co-founder, Dr. Jean-Christophe Harmange, CSO, and Dr. Kathleen Seyb, SVP of Biology.


Get latest news from African Startup ecosystem

Latest stories

You might also like...